Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis - Takeaways - MDSpire

Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis

  • By

  • Wenjuan Li

  • Yanhong Zhao

  • Siyan Shu

  • Ran Li

  • Yu Huang

  • Yuanyuan Gong

  • Guanhua Zhao

  • Yuxin Fan

  • Jianchang He

  • May 1, 2026

  • 0 min

Share

  • 1

    The systematic review assessed the efficacy and safety of biologics and targeted small molecules for systemic lupus erythematosus (SLE) combined with stable background therapy.

  • 2

    Telitacicept and Ustekinumab showed superior efficacy for SLE Responder Index (SRI-4) response compared to other treatments.

  • 3

    Upadacitinib outperformed Baricitinib in achieving BILAG-based Composite Lupus Assessment (BICLA) response and Lupus Low Disease Activity State (LLDAS).

  • 4

    Deucravacitinib and Anifrolumab were more effective than Baricitinib for achieving CLASI-50 improvement in cutaneous manifestations of SLE.

  • 5

    Anifrolumab, Iberdomide, and Telitacicept had higher adverse event rates, while Cenerimod and IL-2 showed lower risks of serious adverse events and infections.

Original Source(s)

Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis

  • by Wenjuan Li, Yanhong Zhao, Siyan Shu, Ran Li, Yu Huang, Yuanyuan Gong, Guanhua Zhao, Yuxin Fan, Jianchang He

  • May 1, 2026

Related Content

Design and Data Gathering Techniques in the Rheumatology Registry

Clinical trial tests promising CAR T-cell therapy for lupus

UCI Health has launched a groundbreaking clinical trial for a next-generation CAR T-cell therapy.

  • by

  • January 13, 2026

  • 1 min
Why autoimmune diseases mostly strike women and are often misdiagnosed